Breaking News Instant updates and real-time market news.

DXCM

DexCom

$58.08

0.09 (0.16%)

, ABT

Abbott

$58.93

0.005 (0.01%)

11:58
01/04/18
01/04
11:58
01/04/18
11:58

Dexcom falls after Abbott receives Medicare approval for Libre

Shares of Dexcom (DXCM) are sinking after Abbott (ABT) announced that FreeStyle Libre, its new continuous glucose monitoring system, is now available to Medicare patients. ABBOTT ANNOUNCES MEDICARE COVERAGE: This morning, Abbott announced that the FreeStyle Libre System, the company's rnew continuous glucose monitoring system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services. Coverage includes all Medicare patients with diabetes who use insulin and who meet the eligibility criteria. Abbott said that the factory-calibrated FreeStyle Libre system is the only CGM system recognized by Medicare that requires no user calibration whatsoever and also does not require the need for routine fingersticks. BUYING OPPORTUNITY: Following Abbott's announcement, Piper Jaffray analyst JP McKim said he believes Abbott's Medicare approval for Libre is "more market-expanding than share-taking" for Dexcom, and maintained an Overweight rating on Dexcom shares, seeing the pullback as a buying opportunity for longer-term investors. The analyst believes the sooner-than-expected Medicare coverage minimizes upside potential for Medicare revenue in 2018, but added that CGM adoption is expected to accelerate and he thinks "the superior product" of Dexcom will win more Medicare patients. NORTHLAND DOWNGRADES: Northland analyst Suraj Kalia downgraded Dexcom to Underperform from Market Perform after Abbott announced Medicare coverage for the Libre FGM. The analyst believes it undercuts Dexcom's competitive advantages, and contends that there is additional headline risk vis-a-vis Medtronic's (MDT) Guardian Connect CGM approval in the pipeline. Further, Kalia believes Dexcom's stock is bound to be under pressure over the next 12-18 months. The analyst added that Dexcom does have the best in class sensor and the company has an "excellent" pipeline but argued that the Libre FGM may be "good enough" for a large chunk of patients, especially as its about one-tenth the cost of Dexcom's upfront price. OTHER ANALYST COMMENTARY: Cowen analyst Doug Schenkel believes shares of Dexcom are down too much following Abbott's announcement and that a 10% sellof "appears disproportionate" on a three month timing swing on an expected event. Baird analyst Jeff Johnson said he believes today's news may not be create as much near-term risk to Dexcom numbers as investors believe. PRICE ACTION: Dexcom dropped 10.8%, or $6.29, to $51.79 at midday.

DXCM

DexCom

$58.08

0.09 (0.16%)

ABT

Abbott

$58.93

0.005 (0.01%)

MDT

Medtronic

$83.44

-0.48 (-0.57%)

  • 04

    Jan

  • 24

    Jan

  • 26

    Feb

DXCM DexCom
$58.08

0.09 (0.16%)

01/04/18
01/04/18
DOWNGRADE

Underperform
Dexcom to Underperform at Northland
As previously reported, Northland analyst Suraj Kalia downgraded Dexcom (DXCM) to Underperform from Market Perform after Abbott (ABT) announced Medicare coverage for its Libre FGM. The analyst believes it undercuts Dexcom's competitive advantages, and contends that there is additional headline risk vis-a-vis Medtronic' (MDT) Guardian Connect CGM approval in the pipeline. Further, Kalia believes Dexcom's stock is bound to be under pressure over the next 12-18 months.
01/04/18
COWN
01/04/18
NO CHANGE
COWN
Dexcom sell-off overdone, says Cowen
01/04/18
COWN
01/04/18
NO CHANGE
Target $70
COWN
Outperform
Dexcom selling off too much on Abbott news, says Cowen
Cowen analyst Doug Schenkel believes shares of Dexcom (DXCM) are down too much after Abbott (ABT) announced Medicare reimbursement for Libre. Given Libre's dosing claim, this development was expected, though it came three months earlier than expected, Schenkel tells investors in a research note. He believes a 10% selloff "appears disproportionate" on a three month timing swing on an expected event. The analyst keeps an Outperform rating on Dexcom with a $70 price target. The stock in late morning trading is down 11% to $51.86.
01/04/18
BARD
01/04/18
NO CHANGE
Target $58
BARD
Neutral
Risk to Dexcom estimates may be less than feared, says Baird
Baird analyst Jeff Johnson says his channel checks indicate Abbott's (ABT) Libre will be reimbursed by Centers for Medicare & Medicaid Services using the same codes as Dexcom's (DXCM) G5, meaning at the same monthly price of $250 per patient. The analyst has long believed superior technology, or G5 over Libre, will win out at price parity. As such, he believes today's news may not be create as much near-term risk to Dexcom numbers as investors believe. The analyst, however, keeps a Neutral rating on Dexcom shares, despite today's 11% selloff. He believes longer-term CMS and commercial payer questions remain.
ABT Abbott
$58.93

0.005 (0.01%)

01/04/18
PIPR
01/04/18
NO CHANGE
PIPR
Dexcom pullback a buying opportunity for longer-term investors, says Piper
Piper Jaffray analyst JP McKim believes Abbott's (ABT) Medicare approval for Libre is "more market-expanding than share-taking" for Dexcom (DXCM), and maintained an Overweight rating on Dexcom shares, seeing the pullback as a buying opportunity for longer-term investors. Dexcom shares are down 8.75% to $53 in late morning trading.
MDT Medtronic
$83.44

-0.48 (-0.57%)

01/02/18
BOFA
01/02/18
UPGRADE
BOFA
Buy
Medtronic upgraded to Buy from Neutral at BofA/Merrill
01/02/18
BOFA
01/02/18
UPGRADE
BOFA
Buy
Medtronic upgraded to Buy at BofA/Merrill
As previously reported, BofA/Merrill upgraded Medtronic to Buy from Neutral and increased its price target to $94 from $90. Analyst Bob Hopkins believes Medtronic is on the "verge" of delivering more consistent growth driven by its pipeline and manufacturing footprint reduction, which should drive multiple expansion.
01/03/18
EVER
01/03/18
INITIATION
Target $92.5
EVER
Outperform
Medtronic initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Medtronic with an Outperform rating and $92.50 price target. The analyst has confidence in the company's revenue growth accelerating in the second half of 2018. He finds the stock "compelling" at current share levels.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

08:13
11/20/18
11/20
08:13
11/20/18
08:13
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRM

Iron Mountain

$33.46

-0.38 (-1.12%)

08:11
11/20/18
11/20
08:11
11/20/18
08:11
Initiation
Iron Mountain initiated  »

Iron Mountain initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOWR

Tower International

$29.99

0.51 (1.73%)

08:11
11/20/18
11/20
08:11
11/20/18
08:11
Hot Stocks
Breaking Hot Stocks news story on Tower International »

Tower International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$16.51

-0.23 (-1.37%)

08:10
11/20/18
11/20
08:10
11/20/18
08:10
Hot Stocks
Clovis issued second U.S. patent covering rucaparib »

Clovis Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BE

Bloom Energy

$14.50

-1.54 (-9.60%)

08:10
11/20/18
11/20
08:10
11/20/18
08:10
Conference/Events
Bloom Energy has a conference call hosted by JPMorgan »

JPMorgan Analyst Coster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

PME

Pingtan Marine Enterprise

$2.35

-0.05 (-2.08%)

08:09
11/20/18
11/20
08:09
11/20/18
08:09
Hot Stocks
Pingtan Marine Enterprise announces three new vessels sailed to sea »

Pingtan Marine Enterprise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRD

Nemaura Medical

$1.87

0.01 (0.54%)

08:09
11/20/18
11/20
08:09
11/20/18
08:09
Hot Stocks
Nemaura Medical signs exclusive license agreement with Al Danah Medical »

Nemaura Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

EQBK

Equity Bancshares

$37.02

-0.7 (-1.86%)

08:08
11/20/18
11/20
08:08
11/20/18
08:08
Initiation
Equity Bancshares initiated  »

Equity Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ESND

Essendant

$12.68

-0.02 (-0.16%)

08:08
11/20/18
11/20
08:08
11/20/18
08:08
Hot Stocks
Staples' affiliates extends expiration of tender offer for Essendant's shares »

Staples announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$7.84

-0.2 (-2.49%)

, BHGE

Baker Hughes

$23.00

-0.38 (-1.63%)

08:07
11/20/18
11/20
08:07
11/20/18
08:07
Recommendations
General Electric, Baker Hughes analyst commentary  »

GE 'fire sale'…

GE

General Electric

$7.84

-0.2 (-2.49%)

BHGE

Baker Hughes

$23.00

-0.38 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

HJLI

Hancock Jaffe Laboratories

$2.02

(0.00%)

08:07
11/20/18
11/20
08:07
11/20/18
08:07
Hot Stocks
Hancock Jaffe Laboratories receives update on VenoValve application from INVIMA »

Hancock Jaffe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

MTEM

Molecular Templates

$4.59

-0.17 (-3.57%)

08:06
11/20/18
11/20
08:06
11/20/18
08:06
Initiation
Molecular Templates initiated  »

Molecular Templates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADI

Analog Devices

$85.55

-3.94 (-4.40%)

08:06
11/20/18
11/20
08:06
11/20/18
08:06
Earnings
Analog Devices sees Q1 adjusted EPS $1.28, plus or minus 7c, consensus $1.35 »

Sees Q1 revenue $1.51B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

KLIC

Kulicke & Soffa

$19.90

-0.96 (-4.60%)

08:05
11/20/18
11/20
08:05
11/20/18
08:05
Initiation
Kulicke & Soffa initiated  »

Kulicke & Soffa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

08:05
11/20/18
11/20
08:05
11/20/18
08:05
General news
U.S. equities are getting de-FAANGed again »

U.S. equities are getting…

08:05
11/20/18
11/20
08:05
11/20/18
08:05
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

BWA

BorgWarner

$39.40

-0.345 (-0.87%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Conference/Events
BorgWarner management to meet with Wolfe Research »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

ADI

Analog Devices

$85.55

-3.94 (-4.40%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Earnings
Analog Devices reports Q4 adjusted EPS $1.55, consensus 1.52 »

Reports Q4 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

WOW

WideOpenWest

$10.02

-0.15 (-1.47%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Conference/Events
WideOpenWest management to meet with JMP Securities »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

  • 03

    Dec

TOWR

Tower International

$29.99

0.51 (1.73%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Hot Stocks
Tower International signs MOU to sell European operations »

Tower International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVFY

Nova Lifestyle

$0.87

-0.03 (-3.33%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Hot Stocks
Nova Lifestyle receives over $1M in orders from Barsala »

Nova LifeStyle announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXTR

Extreme Networks

$6.20

-0.25 (-3.88%)

, HPE

HP Enterprise

$14.83

-0.37 (-2.43%)

08:02
11/20/18
11/20
08:02
11/20/18
08:02
Hot Stocks
Extreme Networks appoints Remi Thomas as CFO »

Extreme Networks (EXTR)…

EXTR

Extreme Networks

$6.20

-0.25 (-3.88%)

HPE

HP Enterprise

$14.83

-0.37 (-2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

TGT

Target

$77.13

-1.9 (-2.40%)

08:02
11/20/18
11/20
08:02
11/20/18
08:02
Recommendations
Target analyst commentary  »

Target sales solid, buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

CBRL

Cracker Barrel

$174.86

5.18 (3.05%)

08:00
11/20/18
11/20
08:00
11/20/18
08:00
Downgrade
Cracker Barrel rating change  »

Cracker Barrel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

MSFT

Microsoft

$104.62

-3.66 (-3.38%)

08:00
11/20/18
11/20
08:00
11/20/18
08:00
Options
Microsoft put buyer realizes 25% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 28

    Nov

  • 04

    Dec

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.